Pancreatina Amilasa + Lipasa + Proteasas Totales shortage — CO supply status & alternatives

Pancreatina Amilasa + Lipasa + Proteasas Totales

—

In supply · Australia

In supply · 🇦🇺 Australia · short in🌐 CO🇵🇹 PT

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Therapeutic category
Active ingredient (INN)	Pancreatina Amilasa + Lipasa + Proteasas Totales

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🌐

INVIMA · 10h ago

High

🇵🇹

INFARMED · 16h ago

Medium

Verified timeline regulator events

🇵🇹 5 July 2026

medium reported

🌐 28 May 2024

medium reported

🌐 11 Oct 2022

high reported

Sources official regulators

🌐

INVIMA

verified 10h ago

verify ↗

🇵🇹

INFARMED

verified 16h ago

verify ↗

Mederti Drug Report

Generated 5 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.